Predictors of psoriasis on response to systemic therapy

Predictors of psoriasis on response to systemic therapy - PREDICT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017896

Enrollment

500

Registered

2019-11-18

Start date

2014-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40

Interventions

Group 1: In patients with moderate to severe plaque PsO and first-time systemic therapy, the achievement of the 2011 European Consensus defined treatment goal was evaluated. Patients were evaluated at

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients (= 18 years) with moderate to severe plaque psoriasis (defined by the European Consensus 2011 [5]) and present indication for conventional systemic psoriasis treatment (fumaric acid ester, MTX, cyclosporine, etc.) who are naive (untreated) to conventional psoriasis system therapy at the time of initiation of observation.

Exclusion criteria

Exclusion criteria: Patients who have already been treated with systemic psoriasis medications, i.e. are "not naive" to systemic psoriasis therapy and/or patients who are receiving PUVA therapy and/or patients who cannot or do not wish to sign the informed consent form

Design outcomes

Primary

Measure	Time frame
1. Document the achievement of the 2011 European Consensus defined treatment goals after initial cessation of systemic treatment in the practical Routine 2. Assess whether or how the following basic parameters influence the achievement of treatment goals or disease course: - severity of disease/extent of skin lesions - quality of life (QoL) - body weight, body mass index, waist and hip circumference, waist-hip ratio diagnosis of hypertension, type I/II diabetes mellitus, hyperlipidaemia - history of disease with myocardial infarction stroke - psoriatic arthritis, tobacco consumption	—

Measure

Time frame

1. Document the achievement of the 2011 European Consensus defined treatment goals after initial cessation of systemic treatment in the practical Routine 2. Assess whether or how the following basic parameters influence the achievement of treatment goals or disease course: - severity of disease/extent of skin lesions - quality of life (QoL) - body weight, body mass index, waist and hip circumference, waist-hip ratio diagnosis of hypertension, type I/II diabetes mellitus, hyperlipidaemia - history of disease with myocardial infarction stroke - psoriatic arthritis, tobacco consumption

—

Secondary

Measure	Time frame
1. Observe the achievement of treatment goals related to other parameters, including: - Psoriasis-associated parameters (age, nail PsO, scalp PsO, age at onset of disease, disease duration concomitant medication (other diseases) 2. Period and number of change of regimen related to the above baseline parameters	—

Countries

Germany

Contacts

Public ContactSusana Gomis-Kleindienst

AbbVie Deutschland GmbH & Co. KG

susana.gomis-kleindienst@abbvie.com+49 611 1720 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026